Brand-name drug
Vraylar price, strengths & recalls
Brand of cariprazine (generic)
Pharmacies pay $1,524.97 for 30 capsules of Vraylar 1.5 mg capsule this week, and from $1,522.89 to $1,525.85 across its 6 priced strengths and forms. It has 1 recall on record, none ongoing. Its official label last changed on August 20, 2026.
Medicare price 2027Brand- Fair cash price
- $1,764.22
- Strengths
- 6
- Makers
- 1
- Updated
- Nov 11
Vraylar price by strength
What pharmacies pay for each strength and form this week (Nov 11, 2026), for the usual package. Choose one for its fair price, 52-week chart and makers.
| Strength and form | Per unit | Pharmacies pay |
|---|---|---|
| 0.5 mg capsule Brand | $50.77 | $1,523.03 / 30 capsules |
| 0.75 mg capsule Brand | $50.81 | $1,524.26 / 30 capsules |
| 1.5 mg capsule Brand | $50.83 | $1,524.97 / 30 capsules |
| 3 mg capsule Brand | $50.86 | $1,525.85 / 30 capsules |
| 4.5 mg capsule Brand | $50.78 | $1,523.48 / 30 capsules |
| 6 mg capsule Brand | $50.76 | $1,522.89 / 30 capsules |
The lowest cost per capsule is 6 mg capsule at $50.76. Strengths aren't interchangeable - ask your pharmacist or prescriber before changing.
Vraylar vs generic cariprazine
There is no generic version of Vraylar on the market yet. Its last listed patent or exclusivity runs to March 17, 2030 - generics often follow, though court cases and settlements can move the date either way.
GenericCariprazine pricesMedicare negotiated price
Medicare negotiated a maximum fair price of $770.00 for a 30-day supply of Vraylar, against a 2024 list price of $1,376.00. It takes effect on January 1, 2027.
What this means for patients
- The negotiated price is what Medicare Part D plans pay for the drug - not your price at the counter.
- What you pay depends on your plan's copay or coinsurance and where you are in the year. Coinsurance (a percentage) falls with the price; a flat copay may not change at all.
- Out-of-pocket costs for Part D drugs are capped each year ($2,100 in 2026), whatever the drug.
- If you don't have Medicare, the negotiated price doesn't apply to you - check the fair cash price above instead.
Supply status: shortages & recalls
Recalls
A recall names specific lots. Check the lot number on your package against the recall before you worry - and don't stop a medicine without asking your pharmacist. What to do if your medication is recalled.
What people paid for Vraylar
Bought it recently? Share the price, the pharmacy and how you paid - it's the most useful thing the next person can read.
Official label & what changed
These highlights do not include all the information needed to use VRAYLAR safely and effectively. See full prescribing information for VRAYLAR. VRAYLAR® (cariprazine) capsules, for oral useInitial U.S. Approval: 2015
WARNING: INCREASED MORTALITY IN ELDERLY PATIENTS WITH DEMENTIA-RELATED PSYCHOSIS and SUICIDAL THOUGHTS AND BEHAVIORS
Increased Mortality in Elderly Patients with Dementia-Related Psychosis
Elderly patients with dementia-related psychosis treated with antipsychotic drugs are at an increased risk of death. VRAYLAR is not approved for the treatment of patients with dementia-related psychosis [see Warnings and Precautions (5.1)].
Suicidal Thoughts and Behaviors
Antidepressants increased the risk of suicidal thoughts and behaviors in pediatric and young adult patients in short-term studies. Closely monitor all antidepressant-treated patients for clinical worsening, and for the emergence of suicidal thoughts and behaviors [see Warnings and Precautions (5.2)].
WARNING: INCREASED MORTALITY IN ELDERLY PATIENTS WITH DEMENTIA-RELATED PSYCHOSIS and SUICIDAL THOUGHTS AND BEHAVIORS
See full prescribing information for complete boxed warning.
Elderly patients with dementia-related psychosis treated with antipsychotic drugs are at an increased risk of death. VRAYLAR is not approved for the treatment of patients with dementia-related psychosis. (5.1)
Antidepressants increased the risk of suicidal thoughts and behaviors in pediatric and young adult patients. Closely monitor all antidepressant-treated patients for clinical worsening and emergence of suicidal thoughts and behaviors. (5.2)
Recent major changes (as listed on the label)
Indications and Usage (1) | 12/2025 |
Dosage and Administration (2.2, 2.3, 2.6) | 12/2025 |
Warnings and Precautions, Metabolic Changes (5.7) | 12/2025 |
We check this label every day. When it changes, the sections that changed appear here, old text beside new.
We show the official text and what changed; we don't interpret it. Ask your pharmacist or prescriber what a change means for you.
Approval, patents & generics
- Application
- NDA204370 · Abbvie
- First approved
- September 17, 2015 (11 years ago)
- Latest approved change
- December 18, 2025
- Approved label
- PDF, Dec 22, 2025
- Generic makers
- None on the market
- Last patent listed
- March 17, 2030
- Exclusivity ends
- June 18, 2029
Patent dates are what the maker lists with FDA. Generic launch dates are often set by court rulings or settlements instead. Upcoming generics.
Vraylar questions
How much does vraylar cost without insurance?
Pharmacies pay about $1,524.97 for 30 capsules of vraylar 1.5 mg capsule ($50.83 per capsule). A fair cash price - that cost plus a 15% margin and a typical dispensing fee - is about $1,764.22. If you're quoted much more, check your quote and ask for the pharmacy's cash price.
Is there a generic for Vraylar?
Yes: cariprazine. Compare cariprazine prices.
Is vraylar in shortage?
No shortage is reported for vraylar right now. We check the national shortage list every day.
Has vraylar been recalled?
1 recall on record, none ongoing. Recalls name specific lots - check yours.
When did the vraylar label last change?
The official label was last updated on August 20, 2026 (version 32). See what changed.
Does Medicare have a negotiated price for Vraylar?
Yes: $770.00 for a 30-day supply of Vraylar, from January 1, 2027. What you pay still depends on your plan.
Talk about vraylar
No comments yet. Questions, tips, what worked for you - start the conversation.